Cover Image
市場調查報告書

Edison Pharmaceuticals, Inc. : 產品平台分析

Edison Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321978
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Edison Pharmaceuticals, Inc. : 產品平台分析 Edison Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 25 Pages
簡介

Edison Pharmaceuticals, Inc.是總公司設立於美國的製藥企業,從事著針對粒腺體功能障礙和其他神經疾病之氧化還原控制異常治療藥的藥物研發及開發。

本報告提供Edison Pharmaceuticals, Inc. 治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Edison Pharmaceuticals, Inc. 的基本資料

  • Edison Pharmaceuticals, Inc. 概要
  • 主要資訊
  • 企業資料

Edison Pharmaceuticals, Inc. :R&D概要

  • 主要的治療範圍

Edison Pharmaceuticals, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Edison Pharmaceuticals, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Edison Pharmaceuticals, Inc. :藥物簡介

  • vatiquinone
  • EPI-589
  • Small Molecules for Metabolic and CNS Disorders

Edison Pharmaceuticals, Inc. :開發平台分析

  • 各給藥途徑
  • 各分子類型

Edison Pharmaceuticals, Inc. :最新的開發平台資訊

Edison Pharmaceuticals, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07514CDB

Summary

Global Markets Direct's, 'Edison Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Edison Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Edison Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Edison Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Edison Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Edison Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Edison Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Edison Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Edison Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Edison Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Edison Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Edison Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Edison Pharmaceuticals, Inc. Snapshot
    • Edison Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Edison Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Edison Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Edison Pharmaceuticals, Inc. - Pipeline Products Glance
    • Edison Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Edison Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Edison Pharmaceuticals, Inc. - Drug Profiles
    • vatiquinone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EPI-589
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Metabolic and CNS Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Edison Pharmaceuticals, Inc. - Pipeline Analysis
  • Edison Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
  • Edison Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
  • Edison Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Edison Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Edison Pharmaceuticals, Inc., Key Information
  • Edison Pharmaceuticals, Inc., Key Facts
  • Edison Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Edison Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Edison Pharmaceuticals, Inc. - Phase II, 2015
  • Edison Pharmaceuticals, Inc. - Phase I, 2015
  • Edison Pharmaceuticals, Inc. - Preclinical, 2015
  • Edison Pharmaceuticals, Inc. - Discovery, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Edison Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Edison Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Edison Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top